Fig. 6: High ratio of CD163+ TAM-to-T cell ratio in tumor biopsies is associated with shorter OS on tebentafusp treatment. | Nature Communications

Fig. 6: High ratio of CD163+ TAM-to-T cell ratio in tumor biopsies is associated with shorter OS on tebentafusp treatment.

From: Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer

Fig. 6

a Kaplan-Meier plot of OS of patients on tebentafusp treatment. Patients stratified by CD163+ TAM, and CD3+ T cells (hazard ratios [HR] and p values using Cox likelihood ratio test are shown). b Kaplan-Meier plot of OS of patients on tebentafusp treatment. Patients stratified by CD163:CD3 high (orange) and low (blue) by lower quantile cutoff (LQ) (n = 117 baseline biopsies from tebentafusp-treated patients, HR and p values using Cox likelihood ratio test are shown). c Representative immunohistochemistry images (from n = 117 individual patients) of tumor infiltrating CD3+ T cells and CD163+ TAM. Low CD163:CD3 ratio (mean) determined as 1:2 (SD±0.3) and high CD163+:CD3+ ratio (mean) is 6:1 (SD±11). d Representative immunofluorescence images (from n = 14 individual patients) of a patient with high CD163: CD3 ratio (DAPI [blue], SOX10 [cyan], CD3 [green], CD163 [red]). Abbreviations: LQ = lower quartile, TAM = Tumor-associated macrophages, HR = Hazard Ratio, CI = Confidence Interval.

Back to article page